Inhibition of gastric inhibitory polypeptide signaling prevents obesity
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Secretion of gastric inhibitory polypeptide (GIP), a duodenal hormone, is primarily induced by absorption of ingested fat. Here we describe a novel pathway of obesity promotion via GIP. Wild-type mice fed a high-fat diet exhibited both hypersecretion of GIP and extreme visceral and subcutaneous fat deposition with insulin resistance. In contrast, mice lacking the GIP receptor (Gipr(-/-)) fed a high-fat diet were clearly protected from both the obesity and the insulin resistance. Moreover, double-homozygous mice (Gipr(-/-), Lep(ob)/Lep(ob)) generated by crossbreeding Gipr(-/-) and obese ob/ob (Lep(ob)/Lep(ob)) mice gained less weight and had lower adiposity than Lep(ob)/Lep(ob) mice. The Gipr(-/-) mice had a lower respiratory quotient and used fat as the preferred energy substrate, and were thus resistant to obesity. Therefore, GIP directly links overnutrition to obesity and it is a potential target for anti-obesity drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“tirzepatide proved superior in improving glycemic control relative to treatment with semaglutide (1 mg)133, insulin degludec134, insulin glargine135,136, and insulin lispro137; importantly, with preserved efficacy and without compromising safety in subjects at risk for cardiovascular diseases136.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [136]
In the citing paper
“Despite the slight differences based on the subject cohort and the duration of treatment, this magnitude of weight loss was largely consistent with the SURPASS trials132-140.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [136]
In the citing paper
“Combined, the SURPASS and SURMOUNT trials have verified the safety of tirzepatide to be consistent with GLP-1R agonists, along with its enhanced efficacy at maximal doses of 5, 10 and 15 mg (Table 1)132-136,143,145-147”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [136]
In the citing paper
“While GIPR antagonism has been shown to reduce adiposity in preclinical models [64], the clinical data show tirzepatide, a dual GLP-1R/GIPR agonist, produces greater weight loss and glucose lowering than the GLP-1R agonist semaglutide alone [42], particularly at doses which comparably engage the GLP-1R [61].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [64]
In the citing paper
“Initial reports that GIPR null mice [64] are protected from diet-induced obesity have been supported by preclinical studies in rodents and non-human primates that GIPR antagonism induces additive weight loss when combined with GLP-1R agonism [32,67], and human genetics data that loss-of-function GIPR variants associate with reduced adiposity [68].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [64]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419 · cited 1×
“Obese Lep ob / Lep ob mice exhibit a marked increase in adipose tissue due to hyperphagia caused by mutation of the leptin gen”
BackgroundSerum Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans
Considine, R. V., Sinha, M. K., Heiman, M. L., Kriauciunas, A., Stephens, T. W., Nyce, M. R., Ohannesian, J. P., Marco, C. C., McKee, L. J., Bauer, T. L., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340503 · Cited by 6,326
The hormone resistin links obesity to diabetes
Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. R., Ahima, R. S., & Lazar, M. A. (2001) · Nature · doi:10.1038/35053000 · Cited by 4,755
Weight-Reducing Effects of the Plasma Protein Encoded by the obese Gene
Halaas, J. L., Gajiwala, K. S., Maffei, M., Cohen, S. L., Chait, B. T., Rabinowitz, D., Lallone, R. L., Burley, S. K., & Friedman, J. M. (1995) · Science · doi:10.1126/science.7624777 · Cited by 4,451
Obesity and insulin resistance
Kahn, B. B., & Flier, J. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10842 · Cited by 3,225
Obesity and the regulation of energy balance
Spiegelman, B. M., & Flier, J. S. (2001) · Cell · doi:10.1016/s0092-8674(01)00240-9 · Cited by 2,398
Frederich, R. C., Hamann, A., Anderson, S., Löllmann, B., Lowell, B. B., & Flier, J. S. (1995) · Nature Medicine · doi:10.1038/nm1295-1311 · Cited by 1,660
Green, H., & Kehinde, O. (1975) · Cell · doi:10.1016/0092-8674(75)90087-2 · Cited by 1,360
Dietary fat intake does affect obesity!
Bray, G. A., & Popkin, B. M. (1998) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/68.6.1157 · Cited by 1,123
Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis
Goldberg, I. J. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37569-6 · Cited by 1,010
Cited by
Items 301–400 of 972
Knerr, P. J., Mowery, S. A., Finan, B., Perez-Tilve, D., Tschöp, M. H., & DiMarchi, R. D. (2020) · Peptides · doi:10.1016/j.peptides.2019.170225 · Cited by 49
Moritoh, Y., Takeuchi, K., & Hazama, M. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01156.x · Cited by 52
“Interestingly, genetic knockout or chemical antagonism of GIP receptor resulted in improved metabolic profiles in obesity-related diabetic models [38,39], indicating that GIP antagonism may be effective for obesity-related diabetes.”
BackgroundUgleholdt, R., Pedersen, J., Bassi, M. R., Füchtbauer, E.-M., Jørgensen, S. M., Kissow, H.-L., Nytofte, N., Poulsen, S. S., Rosenkilde, M. M., Seino, Y., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.311779 · Cited by 49
Self-citationGögebakan, Ö., Andres, J., Biedasek, K., Mai, K., Kühnen, P., Krude, H., Isken, F., Rudovich, N. N., Osterhoff, M. A., Kintscher, U., et al. (2011) · Diabetes · doi:10.2337/db10-0902 · Cited by 49
“Thus, long-term inactivation of GIP signaling in GIP receptor (GIPR) knockout mice resulted in animals resistant to high fat diet–induced obesity (4), and GIPR antagonism reversed obesity, insulin resistance, and associated metabolic disturbances in mice (5).”
BackgroundMethodBorner, T., Tinsley, I. C., Doyle, R. P., Hayes, M. R., & Jonghe, B. C. D. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15647 · Cited by 49
Role of the incretin system in the remission of type 2 diabetes following bariatric surgery
Mingrone, G. (2008) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2008.07.004 · Cited by 54
Pathak, V., Gault, V. A., Flatt, P. R., & Irwin, N. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.10.025 · Cited by 48
McClean, P. L., Irwin, N., Hunter, K., Gault, V. A., & Flatt, P. R. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.317 · Cited by 48
“Thus, both normal and obese-diabetic (ob/ob) mice with genetic knockout of the GIP receptor are protected from diet-induced obesity (Miyawaki et al., 2002).”
BackgroundIncretin Hormones, Obesity and Gut Microbiota
Angelini, G., Russo, S., & Mingrone, G. (2024) · Peptides · doi:10.1016/j.peptides.2024.171216 · Cited by 47
“Genetically obese mice (ob/ob) display an increased density of K cells in the small intestine compared to those on normal diet [29 – 31], while disrupting GIP signaling prevents diet-induced obesity and insulin resistance [32 – 35].”
BackgroundSztanek, F., Tóth, L. I., Pető, A., Hernyák, M., Diószegi, Á., & Harangi, M. (2024) · Biomedicines · doi:10.3390/biomedicines12061320 · Cited by 47
“…of GIP on lipid metabolism are currently unclear; some studies suggest it may increase lipid uptake in adipose tissue and decrease lipolysis [53,54], while others suggest GIP may have lipolytic activity, as adipose tissue from transgenic mice overexpressing GIP has been found to be…”
BackgroundReview: Miglitol has potential as a therapeutic drug against obesity
Sugimoto, S., Nakajima, H., Kosaka, K., & Hosoi, H. (2015) · Nutrition & Metabolism · doi:10.1186/s12986-015-0048-8 · Cited by 53
“GIP promotes fat accumulation [11], whereas”
Ussar, S., Haering, M.-F., Fujisaka, S., Lutter, D., Lee, K. Y., Li, N., Gerber, G. K., Bry, L., & Kahn, C. R. (2017) · Diabetes · doi:10.2337/db15-1349 · Cited by 52
“The latter results in some protection of GIP-deficient mice from HFDinduced obesity (49).”
BackgroundShima, K. R., Ota, T., Kato, K., Takeshita, Y., Misu, H., Kaneko, S., & Takamura, T. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000469 · Cited by 49
Genetics of Obesity in East Asians
Sun, C., Kovacs, P. L., & Guiu‐Jurado, E. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.575049 · Cited by 52
“SEC16B is not only an obesity susceptibility locus in individuals of Asian and European ancestry but also is related to BMI in individuals of African ancestry (Sahibdeen et al., 2018).”
BackgroundInfluentialOld Paradoxes and New Opportunities for Appetite Control in Obesity
Montégut, L., López-Otín, C., Magnan, C., & Kroemer, G. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.02.005 · Cited by 48
Girard, R., Tremblay, S., Noll, C., St‐Jean, S., Jones, C. M., Gélinas, Y., Maloum-Rami, F., Perreault, N., Laplante, M., Carpentier, A. C., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27934-w · Cited by 47
Hansen, K. B., Vilsbøll, T., Bagger, J. I., Holst, J. J., & Knop, F. K. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1605 · Cited by 55
Self-citationPsaltis, J. P., Marathe, J., Nguyen, M. T., Le, R., Bursill, C. A., Marathe, C. S., Nelson, A. J., & Psaltis, P. J. (2024) · Medicinal Research Reviews · doi:10.1002/med.22070 · Cited by 50
“63,64 6 | GLP ‐ 1 RAS IN T2DM AND OVERWEIGHT/OBESITY 6.1 | T2DM Despite the pivotal role that endogenous GLP ‐ 1 plays in regulating body weight and glycemia, its short half ‐ life due to rapid degradation by DPP ‐ 4 precludes its therapeutic use.”
InfluentialRecent Advances in Antidiabetic Drug Therapies Targeting the Enteroinsular Axis
Flatt, P. R., Bailey, C. J., & Green, B. (2009) · Current Drug Metabolism · doi:10.2174/138920009787522124 · Cited by 48
Aoki, K., Masuda, K., Miyazaki, T., Togashi, Y., & Terauchi, Y. (2010) · Endocrine Journal · doi:10.1507/endocrj.k10e-103 · Cited by 46
Reid, D. T., Eller, L. K., Nettleton, J. E., & Reimer, R. A. (2015) · Zeitschrift für Ernährungswissenschaft · doi:10.1007/s00394-015-1047-2 · Cited by 46
“In rodent models, inhibiting GIP receptor signalling can prevent many of the metabolic abnormalities associated with dietary-induced obesity–diabetes [49, 50].”
BackgroundGriffo, E., Cotugno, M., Nosso, G., Saldalamacchia, G., Mangione, A., Angrisani, L., Rivellese, A. A., & Capaldo, B. (2015) · Obesity Surgery · doi:10.1007/s11695-015-1891-4 · Cited by 46
“In addition, there is evidence that the disruption of GIP signaling reduces fat accumulation in adipocytes [20] and that GIP receptor knockout mice exhibit an increased insulin sensitivity [21].”
BackgroundResultFarey, J. E., Preda, T. C., Fisher, O. M., Levert‐Mignon, A., Stewart, R. L., Karsten, E., Herbert, B. R., Swarbrick, M. M., & Lord, R. V. (2016) · Obesity Surgery · doi:10.1007/s11695-016-2302-1 · Cited by 50
“GIP contributes to obesity by promoting energy storage through various anabolic effects on adipose tissue [26]; GIP receptor inhibition reduces adipocyte mass and prevents obesity [27, 28].”
BackgroundGut peptide regulation of food intake – evidence for the modulation of hedonic feeding
Woodward, O. R. M., Gribble, F. M., Reimann, F., & Lewis, J. E. (2022) · The Journal of Physiology · doi:10.1113/jp280581 · Cited by 40
Flatt, P. R. (2007) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2007.034 · Cited by 47
“Degradation: cleaved to inactive GIP(3-42) by dipeptidyl”
BackgroundDirect cardiovascular effects of glucagon like peptide-1
Sheikh, A. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-47 · Cited by 45
“Although the main action of GIP is to provide a stimulus for the release of insulin after an oral glucose challenge, the hormone has also been reported to promote lipid uptake in adipocytes [12].”
BackgroundBuhren, B. A., Gasis, M., Thorens, B., Müller, H. W., & Bosse, F. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.22001 · Cited by 46
“GIP also plays a role in adipocyte biology (Wang et al., 1996; Miyawaki et al., 2002).”
BackgroundThe future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
Andreasen, C. R., Andersen, A., & Vilsbøll, T. (2023) · Diabetologia · doi:10.1007/s00125-023-05966-9 · Cited by 44
“1), limiting interest in developing GIPR agonists to treat type 2 diabetes [18].”
BackgroundGlucose-Dependent Insulinotropic Polypeptide in Incretin Physiology: Role in Health and Disease
Wolfe, M. M., Boylan, M. O., & Chin, W. W. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf006 · Cited by 48
“Adapted from Miyawaki et al 2002 (180). ingested food from stimulating the secretion of GI peptides that modulate circulating glucose and insulin levels (2).”
InfluentialThe structure of wheat bread influences the postprandial metabolic response in healthy men
Eelderink, C., Noort, M. W. J., Sözer, N., Koehorst, M., Holst, J. J., Deacon, C. F., Rehfeld, J. F., Poutanen, K. S., Vonk, R. J., Oudhuis, L. A. A. C. M., et al. (2015) · Food & Function · doi:10.1039/c5fo00354g · Cited by 47
Self-citationMichalakis, K. G., & le Roux, C. W. (2012) · Obesity Surgery · doi:10.1007/s11695-012-0698-9 · Cited by 54
Is there a place for incretin therapies in obesity and prediabetes?
Holst, J. J., & Deacon, C. F. (2013) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2013.01.004 · Cited by 47
“27 Miyawaki, K. et al. (2002) Inhibition of gastric inhibitory polypeptide”
BackgroundSelf-citationNovel dual incretin agonist peptide with antidiabetic and neuroprotective potential
Pathak, N. M., Pathak, V., Gault, V. A., McClean, S., Irwin, N., & Flatt, P. R. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.07.021 · Cited by 43
Association analyses of GIP and GIPR polymorphisms with traits of the metabolic syndrome
Nitz, I., Fisher, E., Weikert, C., Burwinkel, B., Li, Y., Möhlig, M., Boeing, H., Schreiber, S., Schrezenmeir, J., & Döring, F. (2007) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200700048 · Cited by 48
Reduced postprandial GLP ‐1 responses in women with gestational diabetes mellitus
Bonde, L., Vilsbøll, T., Nielsen, T., Bagger, J. I., Svare, J., Holst, J. J., Larsen, S., & Knop, F. K. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12082 · Cited by 45
“reported that development of obesity is prevented in GIP receptor-deficient mice [13].”
BackgroundSelf-citationPeripheral neural targets in obesity
Page, A. J., Symonds, E. L., Peiris, M., Blackshaw, L. A., & Young, R. L. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01951.x · Cited by 48
“There is recent interest in GIP in the obesity setting, given that GIP knockout mice are resistant to dietinduced obesity (Miyawaki et al., 2002).”
BackgroundWNT/β-catenin increases the production of incretins by entero-endocrine cells
García-Martínez, J. M., Chocarro‐Calvo, A., Moya, C. M., & García‐Jiménez, C. (2009) · Diabetologia · doi:10.1007/s00125-009-1429-1 · Cited by 45
“In mouse models, GIP receptor knockout animals are resistant to diet-induced obesity and its associated risk of diabetes [9, 10, 42].”
Backgroundde Graaf‐Roelfsema, E. (2013) · The Veterinary Journal · doi:10.1016/j.tvjl.2013.09.064 · Cited by 50
“Additionally, GIP-receptor knock-out mice gained less weight on a high-fat diet than normal mice (Miyawaki et al., 2002).”
BackgroundPedersen, J., Ugleholdt, R. K., Jørgensen, S. M., Windeløv, J. A., Grunddal, K. V., Schwartz, T. W., Füchtbauer, E. M., Poulsen, S. S., Holst, P. J., & Holst, J. J. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00547.2011 · Cited by 43
“The GIPR-KO mice are reported to be resistant to diet-induced obesity (34), and -cells were found to be more fragile in the GLP-1R-KO mouse (18).”
BackgroundSelf-citationYamane, S., Harada, N., & Inagaki, N. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12467 · Cited by 43
Gasbjerg, L. S., ROSENKILDE, M. M., Meier, J. J., Holst, J. J., & Knop, F. K. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15216 · Cited by 45
“7 This, combined with rodent data pointing to GIP as an obesogenic hormone, 8 for many years dampened the interest in pursuing GIP receptor activation as a strategy for the treatment of type 2 diabetes and obesity.”
BackgroundSelf-citationPleiotropic Actions of the Incretin Hormones
McIntosh, C. H. S., Widenmaier, S. B., & Kim, S. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00002-3 · Cited by 46
Khatun, I., Clark, R. W., Vera, N. B., Kou, K., Erion, D. M., Coskran, T., Bobrowski, W. F., Okerberg, C. V., & Goodwin, B. J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.683359 · Cited by 42
“In preclinical models, increased exposure to dietary lipid is reported to increase GIP levels and mice containing a disrupted GIP receptor gene (Gipr / ) are protected from diet-induced obesity (42).”
BackgroundInsights into incretin-based therapies for treatment of diabetic dyslipidemia
Stemmer, K., Finan, B., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.008 · Cited by 43
“An important role for GIP in lipid storage of adipose tissue is supported by findings from studies in global GIPR KO mice which were protected from diet-induced obesity and insulin resistance [250].”
BackgroundYamada, C., Yamada, Y., Tsukiyama, K., Yamada, K., Yamane, S., Harada, N., Miyawaki, K., Seino, Y., & Inagaki, N. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.09.128 · Cited by 47
Self-citationYoder, S. M., Yang, Q., Kindel, T. L., & Tso, P. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00432.2009 · Cited by 46
Bates, H. E., Campbell, J. E., Ussher, J. R., Baggio, L. L., Maida, A., Seino, Y., & Drucker, D. J. (2012) · Diabetes · doi:10.2337/db11-1060 · Cited by 43
Self-citationEnteroendocrine hormone mimetics for the treatment of obesity and diabetes
Irwin, N., & Flatt, P. R. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.09.009 · Cited by 41
“As such, genetic knockout of the GIP receptor or targeted destruction of GIP secreting K-cells protects against dietary-induced obesity and ameliorates insulin resistance in mice [19,20].”
BackgroundXanthakos, S. A. (2008) · Pathophysiology · doi:10.1016/j.pathophys.2008.04.005 · Cited by 45
“[122] K.”
Glucose-Dependent Insulinotropic Polypeptide Suppresses Peripheral Arterial Remodeling in Male Mice
Mori, Y., Kushima, H., Koshibu, M., Saito, T., Hiromura, M., Kohashi, K., Terasaki, M., Seino, Y., Yamada, Y., & Hirano, T. (2018) · Endocrinology · doi:10.1210/en.2018-00336 · Cited by 43
Self-citationThe glucose-dependent insulinotropic polypeptide signaling axis in the central nervous system
Adriaenssens, A. E., Gribble, F. M., & Reimann, F. M. (2019) · Peptides · doi:10.1016/j.peptides.2019.170194 · Cited by 44
Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity
Opinto, G., Natalicchio, A., & Marchetti, P. (2013) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2013.812664 · Cited by 51
“Knock-out of the GIP R confers resistance to diet-induced obesity in mice (Miyawaki et al., 2002), although there is no clear evidence at present to suggest an association between GIP and obesity in humans.”
BackgroundRamesh, N., Mortazavi, S., & Unniappan, S. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.04.100 · Cited by 45
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Hiki, M., Shimada, K., Kiyanagi, T., Fukao, K., Hirose, K., Ohsaka, H., Fukushima, Y., Kume, A., Matsumori, R., Sumiyoshi, K., et al. (2010) · Circulation Journal · doi:10.1253/circj.cj-10-0013 · Cited by 43
Posovszky, C., & Wabitsch, M. (2014) · Hormone Research in Paediatrics · doi:10.1159/000368898 · Cited by 47
Milk minerals and the metabolic syndrome
Scholz-Ahrens, K. E., & Schrezenmeir, J. (2006) · International Dairy Journal · doi:10.1016/j.idairyj.2006.06.009 · Cited by 40
Relling, A. E., Pate, J. L., Reynolds, C. K., & Loerch, S. C. (2009) · Journal of Animal Science · doi:10.2527/jas.2009-2316 · Cited by 46
“This assumption has not been proven in ruminants; however, the importance of GIP in energy redistribution has been studied in mice (Miyawaki et al., 2002), in which the absence of a GIP receptor caused mice to be leaner than mice with a functional GIP receptor.”
BackgroundGLP1R and GIPR expression and signaling in pancreatic alpha cells, beta cells and delta cells
Shilleh, A. H., Viloria, K., Broichhagen, J., Campbell, J. E., & Hodson, D. J. (2024) · Peptides · doi:10.1016/j.peptides.2024.171179 · Cited by 39
“Lastly, GIP-induced glucagon secretion augments insulin secretion, an effect further amplified by prior application of alanine, but abolished by alpha cell-specific GIPR deletion i.e. GIP engages positive alpha cell → beta cell crosstalk via the alpha cell GIPR [96].”
Yamane, S., Harada, N., Hamasaki, A., Muraoka, A., Joo, E., Suzuki, K., Nasteska, D., Tanaka, D., Ogura, M., Harashima, S., et al. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00143.x · Cited by 40
Gault, V. A., Martin, C. M., Flatt, P. R., Parthsarathy, V., & Irwin, N. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0681-0 · Cited by 39
“Although modulation of GIP receptor signalling can affect respiratory quotient, it does not change oxygen consumption [16, 27], as such xenin and GIP may have further similarities here.”
BackgroundDistribution and Stimulus Secretion Coupling of Enteroendocrine Cells along the Intestinal Tract
Adriaenssens, A. E., Reimann, F., & Gribble, F. M. (2018) · Comprehensive physiology · doi:10.1002/cphy.c170047 · Cited by 41
Resistant starch as a novel dietary strategy to maintain kidney health in diabetes mellitus
Koh, G. Y., & Rowling, M. J. (2017) · Nutrition Reviews · doi:10.1093/nutrit/nux006 · Cited by 39
Hjuler, S. T., Andreassen, K. V., Gydesen, S., Karsdal, M. A., & Henriksen, K. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.05.051 · Cited by 41
“…of GIP signalling, either chemical or genetic disruption has been reported to protect against obesity and insulin resistance and adipose inflammation at least in rodents (Irwin and Flatt, 2009;Miyawaki et al., 2002;McClean et al., 2007;Gault et al., 2007;Ahlqvist et al., 2013;Zhou et al., 2005).”
Boer, G. A., Keenan, S. N., Miotto, P. M., Holst, J. J., & Watt, M. J. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00646.2020 · Cited by 38
Self-citationGut hormone GIP induces inflammation and insulin resistance in the hypothalamus
Fu, Y., Kaneko, K., Lin, H.-Y., Mo, Q., Xu, Y., Suganami, T., Ravn, P., & Fukuda, M. (2020) · Endocrinology · doi:10.1210/endocr/bqaa102 · Cited by 38
Jensen, M., Sanni, S. J., Riber, D., Holst, J. J., ROSENKILDE, M. M., & Sparre‐Ulrich, A. H. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102006 · Cited by 42
Self-citationIrwin, N., McClean, P. L., Patterson, S., Hunter, K., & Flatt, P. R. (2008) · Biological Chemistry · doi:10.1515/bc.2009.002 · Cited by 38
Gut carbohydrate inhibits GIP secretion via a microbiota/SCFA/FFAR3 pathway
Lee, E., Zhang, X., Miyamoto, J., Kimura, I., Taknaka, T., Furusawa, K., Jomori, T., Fujimoto, K., Uematsu, S., & Miki, T. (2018) · Journal of Endocrinology · doi:10.1530/joe-18-0241 · Cited by 38
Self-citationGabe, M. B. N., van der Velden, W. J. C., Smit, F. X., Gasbjerg, L. S., & Rosenkilde, M. M. (2020) · Peptides · doi:10.1016/j.peptides.2019.170224 · Cited by 37
“GIPR gene deletion in mice resulted in improved glycaemic control and in a protection against diet induced-obesity [37, 38].”
Dong, T. S., Katzka, W. R., Yang, J. C., Chang, C., Arias-Jayo, N., Lagishetty, V., Balioukova, A., Chen, Y., Dutson, E., Li, Z., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2167170 · Cited by 39
“Despite the rising tide of NAFLD incidence, there are currently no approved medications for the treatment or prevention of NAFLD.”
BackgroundInfluentialNew Function for an Old Enzyme: NEP Deficient Mice Develop Late-Onset Obesity
Becker, M., Siems, W., Kluge, R., Gembardt, F., Schultheiss, H., Schirner, M., & Walther, T. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012793 · Cited by 39
“As described for wild-type animals before, increasing leptin levels in NEP-deficient mice correlated with increasing body weight [9,21] (Figure 3c).”
Schnell, O., Weng, J., Sheu, W. H., Watada, H., Kalra, S., Soegondo, S., Yamamoto, N., Rathod, R., Zhang, C., & Grzeszczak, W. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.01.023 · Cited by 42
“by glucose absorption speed and site of absorption (Irwin et al., 2007; McClean et al., 2007; Miyawaki et al., 2002; Suzuki et al., 2013; Yabe & Seino, 2013).”
BackgroundKomazawa, N., Matsuda, M. E., Kondoh, G., Mizunoya, W., Iwaki, M., Takagi, T., Sumikawa, Y., Inoue, K., Suzuki, A., Mak, T. W., et al. (2005) · Nature Medicine · doi:10.1038/nm0605-691a · Cited by 38
“We used eight acrylic metabolic chambers, gas analyzers (model RL-600) and a switching system (model ANI6-A-S) to sample gas from each metabolic chamber in order to measure oxygen consumption in the mice, as described in detail previousl”
Self-citationRetractedStimulating intestinal GIP release reduces food intake and body weight in mice
Lewis, J. E., Nuzzaci, D., James-Okoro, P.-P., Montaner, M., O’Flaherty, E. A. A., Darwish, T., Hayashi, M., Liberles, S. D., Hornigold, D. C., Naylor, J., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101945 · Cited by 37
“A number of key studies have suggested that GIP might promote weight gain: global germline GIPR knockout mice on a HFD display reduced body weight and maintain insulin sensitivity, whilst in patients with type 2 diabetes (T2D), the insulinotropic effect of GIP is impaired [4,6].”
BackgroundLiu, C. M., Killion, E. A., Hammoud, R., Lu, S.-C., Komorowski, R., Liu, T., Kanke, M., Thomas, V. A., Cook, K. D., Sivits, G. N., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01295-w · Cited by 44
“In addition to the neuropharmacological effects of GIPR antagonism, we also demonstrate that CNS GIPR KO prevents body weight gain under HFD challenge, supporting the role of CNS GIPR as a primary driver of body weight differences seen in the whole-body GIPR KO mouse 41 .”
Nakamura, T., Tanimoto, H., Mizuno, Y., Okamoto, M., Takeuchi, M., Tsubamoto, Y., & Noda, H. (2018) · Obesity Science & Practice · doi:10.1002/osp4.164 · Cited by 38
“Gastric inhibitory polypeptide receptor knock-out mice fed high-fat diets showed suppression of body weight gain compared with wild mice fed the same high-fat diets (19).”
BackgroundSelf-citationNMR and Alanine Scan Studies of Glucose-dependent Insulinotropic Polypeptide in Water
Alaña, I., Parker, J. C., Gault, V. A., Flatt, P. R., O'Harte, F. P. M., Malthouse, J. P. G., & Hewage, C. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510414200 · Cited by 37
Gut: A key player in the pathogenesis of type 2 diabetes?
Muscogiuri, G., Balercia, G., Barrea, L., Cignarelli, A., Giorgino, F., Holst, J. J., Laudisio, D., Orio, F., Tirabassi, G., & Colao, A. (2016) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2016.1252712 · Cited by 38
Self-citationIsken, F., Weickert, M. O., Tschöp, M. H., Nogueiras, R., Möhlig, M., Abdelrahman, A., Klaus, S., Thorens, B., & Pfeiffer, A. F. (2009) · Diabetologia · doi:10.1007/s00125-009-1466-9 · Cited by 36
“GIP is released following fat or carbohydrate consumption and modulates insulin secretion, as well as fat metabolism [19] and locomotor activity [20].”
BackgroundInfluentialMechanisms of bariatric surgery for weight loss and diabetes remission
Yin, M., Wang, Y., Han, M., Liang, R., Li, S., Wang, G., & Gang, X. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13443 · Cited by 46
“51,53,54 The metabolic benefits of bypass surgery are mediated in part by surgical removal of GIP-secreting K cells in the proximal small intestine 55,56 and emerging evidences have also shown that a rapid reduction in GIP levels following RYGB 57 and BPD. 58,59 Treatment of obese mice with GIP…”
Kubow, S. J., Hobson, L., Iskandar, M. M., Sabally, K., Donnelly, D. J., & Agellon, L. B. (2014) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201400013 · Cited by 42
“The lowered plasma gastric inhibitory peptide levels in female mice supplemented with PRPE (Supporting Information Table 3) could partly account for the anti-obesity efficacy of PRPE as elevated plasma levels of this peptide are linked with dietinduced obesity [23].”
BackgroundSearching for the physiological role of glucose‐dependent insulinotropic polypeptide
Holst, J. J., Windeløv, J. A., Boer, G. A., Pedersen, J., Svendsen, B., Christensen, M., Torekov, S., Asmar, M., Hartmann, B., & Nissen, A. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12488 · Cited by 36
Self-citationHarada, N., Hamasaki, A., Yamane, S., Muraoka, A., Joo, E., Fujita, K., & Inagaki, N. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00078.x · Cited by 37
Shimotoyodome, A., Fukuoka, D., Suzuki, J. S., Fujii, Y., Mizuno, T., Meguro, S., Tokimitsu, I., & Hase, T. (2009) · Endocrinology · doi:10.1210/en.2008-1162 · Cited by 36
Lu, W. J., Yang, Q., Sun, W. Y., Woods, S. C., D’Alessio, D. A., & Tso, P. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00400.2007 · Cited by 39
“Subsequent studies have shown that GIP is essential for normal glucose tolerance (47, 61).”
BackgroundOn the role of the incretin hormones GIP and GLP-1 in the pathogenesis of Type 2 diabetes mellitus.
Vilsbøll, T. (2004) · PubMed · Cited by 44
Komazawa, N., Matsuda, M., Kondoh, G., Mizunoya, W., Iwaki, M., Takagi, T., Sumikawa, Y., Inoue, K., Suzuki, A., Mak, T. W., et al. (2004) · Nature Medicine · doi:10.1038/nm1117 · Cited by 36
Self-citationRetractedGIP’s involvement in the pathophysiology of type 2 diabetes
Christensen, M. B., Gasbjerg, L. S., Heimbürger, S. M., Stensen, S., Vilsbøll, T., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170178 · Cited by 35
Liu, H., Xiao, H., Lin, S., Zhou, H., Cheng, Y., Xie, B., & Xu, D. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1372399 · Cited by 40
Self-citationJiang, Y., Zhu, H., & Gong, F. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16106 · Cited by 36
“96 So far, precise mechanism by which GLP-1 agonism combined with GIP agonism or antagonism both induce weight reduction in humans is still unclear, except the proposal that activation of GIP receptors is accompanied by receptor internalization and desensitization that mimics the effects of GIP…”
Mechanisms of Weight Loss after Gastric Bypass and Gastric Banding
Bueter, M., Ashrafian, H., & le Roux, C. W. (2009) · Obesity Facts · doi:10.1159/000232383 · Cited by 35
Aoki, K., Kamiyama, H., Yoshimura, K., Shibuya, M., Masuda, K., & Terauchi, Y. (2011) · Acta Diabetologica · doi:10.1007/s00592-011-0322-9 · Cited by 35
“The inhibition of GIP signaling is beneficial for preventing obesity, as previously reported [31].”
ResultThe gut hormone receptor GIPR links energy availability to the control of hematopoiesis
Pujadas, G., Varin, E. M., Baggio, L. L., Mulvihill, E. E., Bang, K. W. A., Koehler, J. A., Matthews, D., & Drucker, D. J. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101008 · Cited by 35
Kaneko, S. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.1.10 · Cited by 58
Relevance and consequence of chronic inflammation for obesity development
Rück, L., Wiegand, S., & Kühnen, P. (2023) · Molecular and Cellular Pediatrics · doi:10.1186/s40348-023-00170-6 · Cited by 35
“Acute inhibition of GIPR using neutralizing antibodies has shown the ability to substantially reduce body weight and improve obesity by enhancing the effectiveness of leptin [231, 235, 244, 245].”
BackgroundDipeptidyl Peptidase IV Inhibitors: A New Paradigm in Type 2 Diabetes Treatment
Janardhan, S., & Sastry, G. N. (2014) · Current Drug Targets · doi:10.2174/1389450115666140311102638 · Cited by 39
Insulin Action in the Double Incretin Receptor Knockout Mouse
Ayala, J. E., Bracy, D. P., Hansotia, T., Flock, G. B., Seino, Y., Wasserman, D. H., & Drucker, D. J. (2007) · Diabetes · doi:10.2337/db07-0704 · Cited by 35
“This was also observed in a model of genetic obesity, the ob/ob mouse, crossed with GIPR knockout mice (13).”
BackgroundSelf-citationTransgenic animal models for the study of adipose tissue biology
Blüher, M. (2005) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2005.07.006 · Cited by 41
Liu, T., Ji, R.-L., & Tao, Y.-X. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108044 · Cited by 34
Metadata
- Authors
- Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., Hiai, H., Mizunoya, W., Fushiki, T., Holst, J. J., Makino, M., Tashita, A., Kobara, Y., Tsubamoto, Y., Jinnouchi, T., Jomori, T., & Seino, Y.
- Affiliations
- Kyoto University (JP)
- University of Copenhagen (DK)
- Sanwa Kagaku Kenkyusho Co., Ltd. (Japan) (JP)
- Corresponding author
- Seino, Yutaka
- Venue
- Nature Medicine
- Published
- 2002-06-17
- Volume
- 8
- Issue
- 7
- Pages
- 738-742
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2102392334
- Cited by
- 963
- References
- 24
- Citations by year
- 2026: 34 · 2025: 43 · 2024: 64 · 2023: 45 · 2022: 38 · 2021: 39 · 2020: 37 · 2019: 66 · 2018: 39 · 2017: 45 · 2016: 38 · 2015: 42 · 2014: 44 · 2013: 38 · 2012: 38
- FWCI
- 7.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glucose-dependent insulinotropic polypeptide, GIP receptor, obesity, insulin resistance, high-fat diet, adiposity, respiratory quotient, fat oxidation, anti-obesity drugs, overnutrition
- MeSH terms
- Adipose Tissue, Animals, Body Weight, Crosses, Genetic, Dietary Fats, Gastric Inhibitory Polypeptide, Obesity, Receptors, Gastrointestinal Hormone, Signal Transduction, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.